Hjem
Lars A. Akslens bilde

Lars A. Akslen

Professor, Leder for CCBIO
  • E-postLars.Akslen@uib.no
  • Telefon+47 55 97 31 82
  • Besøksadresse
    Patologisk avdeling, Sentralblokka 2 etg., Haukeland Universitetssjukehus (HUS)
    evt. CCBIO, Sentralblokka 2 etg., HUS
  • Postadresse
    Postboks 7804
    5020 Bergen

Akslen er en sertifisert spesialist i kirurgisk patologi og leder forskningsgruppen Tumor Biology Research Group (etablert i 1995) ved Klinisk Institutt 1, Universitetet i Bergen. Siden 2013 har Akslen vært senterleder for Centre for Cancer Biomarkers CCBIO. Akslens gruppe og CCBIO arbeider med translasjonell kreftforskning med fokus på nye kreftmarkører og målrettet behandling og særlig mekanismer knyttet til hvordan kreftceller påvirkes av mikromiljøet i svulstene, og den betydning dette har for kreftspredning og dårlig prognose. Gruppen har prosjekter på ulike kreftformer, som brystkreft, ondartet melanom, prostatakreft og gynekologisk kreft. Gruppen kombinerer studier av humane tumorprøver med eksperimentelle celle- og dyremodeller. Det overordnede målet er å finne nye biomarkører som kan hjelpe oss til å forutse hvordan aggressive svulster vil utvikle seg og dermed bedre kunne skreddersy behandling.

Vitenskapelig artikkel
  • 2010. Expression of aldehyde dehydrogenase a (ALDH1) is associated with basal-like markers and features of aggressive tumors in African breast cancer. British Journal of Cancer. 369-375.
  • 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • 2009. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proceedings of the National Academy of Sciences of the United States of America. 12115-12120.
  • 2009. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Research. 4708-4715.
  • 2009. Hyperoxic treatment induces mesenchymal to epithelial transition in a rat adenocarcinoma model. PLOS ONE.
  • 2008. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • 2008. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
  • 2008. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Modern Pathology. 583-590.
  • 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • 2007. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 11 sider.
  • 2007. Increased expression of sim2-s protein is a novel marker of aggressive prostate cancer. Clinical Cancer Research. 892-897.
  • 2007. Frequency of the basal-like phenotype in African breast cancer. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 1391-1399.
  • 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • 2007. A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer. Clinical Cancer Research. 7003-7011.
  • 2006. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Research. 3303-3309.
  • 2006. Role of angiogenesis in human tumor dormancy - Animal models of the angiogenic switch. Cell Cycle. 1779-1787.
  • 2006. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
  • 2006. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. International Journal of Cancer. 1227-1233.
  • 2006. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical 14 retropubic prostatectomy for localized prostate cancer? BJU International. 51-55.
  • 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • 2006. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
  • 2006. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research. 1168-1174.
  • 2006. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Archiv. 68-74.
  • 2006. Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer. 366-370.
  • 2006. A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. Journal of the National Cancer Institute. 316-325.
  • 2005. Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. British Journal of Cancer. 933-938.
  • 2005. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. Journal of Urology. 425-428.
  • 2005. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research. 8606-8614.
  • 2005. Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.
  • 2005. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Research. 634-644.
  • 2005. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
  • 2005. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes, Chromosomes and Cancer. 10-18.
  • 2005. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiology, Biomarkers and Prevention. 1108-1112.
  • 2004. The prognostic implication of the basal-like (cyclin E-high/p27(low)/p53(+)/glomeruloid-microvascular-proliferation(+)) phenotype of BRCA1-related breast cancer. Cancer Research. 830-835.
  • 2004. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology. 1615-1623.
  • 2004. Prognostic impact of histological grade and vascular invasion compared with tumor cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 472-479.
  • 2004. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. Journal of Clinical Oncology. 1242-1252.
  • 2004. Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
  • 2004. Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
  • 2004. Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma. Clinical Cancer Research. 5367-5374.
  • 2004. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. International Journal of Oncology. 1559-1565.
  • 2003. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 1011-1018.
  • 2003. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology. 218-25.
  • 2003. MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology. 389-94.
  • 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
  • 2003. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research. 1474-1479.
  • 2001. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Research. 7 sider.
  • 2001. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiology, Biomarkers and Prevention. 113-117.
  • 2000. Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Research. 4857-62.
  • 1999. The PTEN gene is methylated in endometrial carcinoma and associated with advanced disease and microsattelite instability. (Abs. no. 207). American Journal of Human Genetics. S. 209.
  • 1999. TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • 1999. TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
  • 1999. Strong prognostic influence of reduced p16 protein expression in endometrial carcinomas. A large population based study. (Abstract no. 0-079). Virchows Archiv. 185.
  • 1999. Significance of tumor associated macrophages. VEGF and TSP-1 expression for tumor angiogenesis and prognosis in endometrial carcinomas. International Journal of Cancer. 539-543.
  • 1999. Significance of tumor associated macrophages, VEGF and TSP-1 for angiogenesis and prognosis of endometrial carcinoma. International Journal of Cancer. 538-43.
  • 1999. Prognostic value of tumor angiogenesis, Ki67, p53 and p21 protein expression - a population based endometrial carcinoma study. Journal of Clinical Oncology. 595-99.
  • 1999. Prognostic significance of tumor angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. Journal of Clinical Oncology. 1382-1390.
  • 1999. Prognostic significance of angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. International Journal of Oncology. 395-399.
  • 1999. Loss of nuclear expression of p16 protein correlates with increased tumor cell proliferation and poor patient outcome in patients with vertical growth phase melanoma. (Abstract no. P-487). Virchows Archiv. 314.
  • 1999. Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • 1999. Enhanced expression of EGF-receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours. Virchows Archiv. 434-441.
  • 1999. Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • 1999. Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • 1999. Angiogenesis is prognostically important in vertical growth phase melanomas. International Journal of Oncology. 595-599.
  • 1998. Økt forekomst av kreft i skjoldkjertelen blant norske kvinner gift med fiskere. Tidsskrift for Den norske legeforening. 4202-4205.
  • 1998. Seasonal variations in the presentation and growth of thyroid cancer. British Journal of Cancer. 1174-1179.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • 1998. Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer. 956-964.
  • 1998. Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
  • 1998. Poorer survival of nulliparous women with endometrial carcinoma. Cancer. 1328-1333.
  • 1998. Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • 1998. Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • 1998. Identification of high-risk patients by assessment of nuclear Ki67 expression in a prosepective study of endometrial carcinoma patients. Clinical Cancer Research. 2779-2785.
  • 1998. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clinical Cancer Research. 2779-2785.
  • 1998. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
  • 1998. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
  • 1998. Diagnostisk molekylærbiologi ved solide svulster: Thyreoideacancer. Tidsskrift for Den norske legeforening. 2199-2203.
  • 1998. Diagnostisk molekylærbiologi ved solide svulster - thyreoidea. Tidsskrift for Den norske legeforening. 2199-2203.
  • 1998. Decreased survival for nulliparous women with endometrial carcinoma. Is the relationship due to biology or behaviour? Cancer. 1328-1333.
  • 1997. Recurrent endometrial carcinoma and the value of routine follow-up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • 1997. Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • 1997. Prognostisk betydning av tumorbiologiske markører ved kreft i livmorslimhinnen. Kreftnytt. 4-7.
  • 1997. Increased risk of thyroid cancer among Norwegian females married to fishery workers. British Journal of Cancer. 385-389.
  • 1997. Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia and benign/hyperplastic glands. Urologic Oncology. 59-66.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1996. Thyroid carcinomas with tall-cell and columnar-cell features (letter). Current Diagnostic Pathology. 67.
  • 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Relationship between mutations in the TP53 gene and De Novo resistance and early relapse following treatment with doxorubicin in patients with breast cancer. Nature Medicine. 811-814.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary organ-culture of non neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1996. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1211-1219.
  • 1996. Incidence of thyroid cancer in New Caledonia, South Pacific, during 1985-1992 (letter). American Journal of Epidemiology. 1174.
  • 1996. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Research. 1184-1188.
  • 1996. Aggressive thyroid carcinoma with predominant cribriform growth pattern. Pathology, Research and Practice.
  • 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1995. Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • 1995. Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (p29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patients survival. Cancer. 1643-1654.
  • 1995. Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patient survival. Cancer. 1643-1654.
  • 1995. Lack of diagnostic value of DNA content and p53 immunostaining in normal, hyperplastic and neoplastic parathyroid tissue. Oncology Reports. 69-72.
  • 1995. Histopatologiens betydning for vurdering av kreftforekomst og kreftårsaker. Tidsskrift for Den norske legeforening. 943-946.
  • 1994. Ploidy and proliferative rates in carcinomas of the breast in Tanzania. East African Medical Journal. 195-198.
  • 1994. Increase of endo-and exo-peptidases in thyroid tumors. Oncol Rep. 953-956.
  • 1993. Thyroid cancer in children in Norway 1953-1987. European Journal of Cancer. 365-366.
  • 1993. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
  • 1993. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 2680-2685.
  • 1993. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer. 808-812.
  • 1993. Incidence pattern of thyroid cancer in Norway: influence of birth cohort and time period. International Journal of Cancer. 183-187.
  • 1993. Demonstration of a TGF-_a-EGF receptor autocrine loop and c-myc protein overexpression in papillary thyroid carcinomas. International Journal of Cancer. 37-43.
  • 1992. Thyroid carcinoma. Results from surgical treatment in 211 consecutive patients. European Journal of Surgery. 521-526.
  • 1992. Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway. European Journal of Cancer. 491-495.
  • 1992. Reproductive factors and risk of thyroid cancer. A prospective study of 63090 women from Norway. British Journal of Cancer. 772-774.
  • 1992. Expression of p53 protein in cutaneous melanoma. International Journal of Cancer. 13-16.
  • 1992. Expression of c-erbB-2 protein in papillary thyroid carcinomas. British Journal of Cancer. 832-837.
  • 1992. Disease free and cause specific survival in patients with papillary thyroid carcinoma. A multifactorial analysis. European Journal of Surgery. 583-589.
  • 1992. Differentiated thyroid carcinomas: the relevance of various pathological features for tumour classification and prediction of tumour progress. Virchows Archiv. A, Pathological anatomy and histopathology. 17-23.
  • 1991. Thyroid carcinoma: Results from surgical treatment in 211consecutive patients. European Journal of Surgery. 521-526.
  • 1991. Thyroid carcinoma. Results from a uniform surgical strategy 1971-1985. Acta Chirurgica Scandinavica. 521-526.
  • 1991. Survival and cause of death in thyroid cancer: A population-based study of 2479 cases from Norway. Cancer Research. 1234-1241.
  • 1991. Squamous cell carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology. 275-276.
  • 1991. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. British Journal of Urology. 61-69.
  • 1991. Periodicity in metastatic tumour growth demonstrated in human liver at autopsy. Invasion Metastasis. 58-64.
  • 1990. Provocation of thyroid neoplasms in female Wistar rats fed n-3 or n-6 fatty acids in the feed. Thyroidology. 1-3.
  • 1990. Increased content of chronium and nickel in lung tissues patients with bronchial carcinoma. Pathology, Research and Practice. 717-722.
Vitenskapelig foredrag
  • 2016. Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences.
  • 2016. FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
  • 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • 2013. Molekylære subtyper og overlevelse ved brystkreft.
  • 2012. Multimodal imaging for suspected recurrent differentiated thyroid cancer (DTC): FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • 2011. Multimodal imaging for diagnosis and treatment of recurrent differentiated thyroid cancer (DTC)FDG-PET-CT, contrast-enhanced CT (CE-CT), I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • 2011. In vivo Dynamic Contrast Enhanced MRI & Histopathological Assessment of Tumor Angiogenesis in Luminal-like and Basal-like Breast Cancer Xenografts.
  • 2011. FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB) for recurrent differentiated thyroid cancer (DTC).
  • 2011. Early vascular response to bevacizumab treatment measured by DCE-MRI in breast cancer xenografts.
  • 2011. DCE-MRI for early therapy monitoring of anti-angiogenic therapy.
  • 2010. Real time elastografi ved cancer prostatae.
  • 2010. Preliminære resultater av PCA3 måling i urin hos pasienter med cancer prostatae.
  • 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound.
  • 2010. In vivo magnetic resonance imaging and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
  • 2010. Er preoperativ MR-prostata nyttig for å avklare korrekt T-stadium forut for kirurgi?
  • 2010. Er MR-prostata nyttig for å avklare videre oppfølgningsbehov hos pasienter med 2 eller flere negative biopsiserier?
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • 2009. EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • 2008. Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • 2008. Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • 2007. Functional oncogenomics and epigenomics analysis of prostate cancer.
  • 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • 2006. ERG upregulation and related transcription factors in prostate cancer.
  • 2004. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • 2004. Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • 2003. Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas.
  • 2003. Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
  • 2003. Global analysis of gene expression and regulatory patterns in cancer.
  • 2003. Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
  • 2003. Gene expression profiling in prostate cancer: Cluster analysis and association with tumor differentiation.
  • 2003. Gene expression profiling in prostate cancer.
  • 2003. DNA microarray studies of human cancer - pitfalls and outlook.
  • 2003. Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.
  • 2002. Cancer mammae behandlet med brystbevarende kirurgi ved Haukeland sykehus 1984-1995.
  • 2001. Prognostisk betydning av angiogenese (microvessel density - MVD) og proliferasjonsmarkøren Ki-67 ved lokalisert prostatacencer.
  • 1999. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • 1998. Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • 1998. Profylaktisk thyroidectomi hos barn - initial erfaring.
  • 1998. Malignt melanom på hender.
  • 1998. Malignant melanoma of the hand. A 25-year clinico-pathological study.
  • 1997. Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].
  • 1989. Mortality form ischemic heart disease related to life-style differences among Norwegian men (Abstract).
Vitenskapelig antologi/Konferanseserie
  • 2017. Biomarkers of the Tumor Microenvironment: Basic Studies and Practical Applications. Springer.
Sammendrag/abstract
  • 2013. Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
  • 2013. Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
  • 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
  • 2012. Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
  • 2012. Metabolic Responses to VEGF Inhibition in Patient-derived Breast Cancer Xenografts. European Journal of Cancer. S32-S32.
  • 2012. Expression of hypoxia-inducible factor-1a and associations with vascular endothelial growth factor expression, high microvessel density and features of aggressive tumors in African breast cancer. Virchows Archiv. S249-S249.
  • 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • 2010. Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 248-248.
  • 2010. Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound [Abstract]. European Journal of Nuclear Medicine and Molecular Imaging. S291-S291.
  • 2009. Proliferation of immature tumor vessels is a novel marker of clinical progress in prostate cancer. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 233-233.
  • 2008. Vascular proliferation by Nestin/Ki-67 is a novel predictor of the clinical progress of prostate cancer. Histopathology. 276-277.
  • 2008. Candidate stem cell marker ALDH1 expression and relationship with BRCA-mutations and basal-like differentiation in breast carcinoma. Histopathology. 25-25.
  • 2007. Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
  • 2007. Epithelial to mesenchymal transition is of strong prognostic importance in prostate cancer. Virchows Archiv. 344-344.
  • 2007. Basal-like phenotype is frequent in invasive breast carcinoma from Ugandan Africans and is strongly associated with a high expression of EGFR/c-Kit and features of aggressive tumors. Virchows Archiv. 137-137.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • 2006. ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • 2005. Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Vitenskapelig oversiktsartikkel/review
  • 2013. Malignt melanom – diagnostikk, behandling og oppfølging i Norge. 2154-2159.
  • 2009. Biologic markers in endometrial cancer treatment. 693-707.
  • 2008. Tumor-vascular interactions and tumor dormancy. 569-585.

Se fullstendig oversikt over publikasjoner i CRIStin.